Treatment Strategies for Therapy-related Acute Myeloid Leukemia

Potentially Curative Therapeutic Activity of NEO212, a Perillyl Alcohol-Temozolomide Conjugate, in Preclinical Cytarabine-Resistant Models of Acute Myeloid Leukemia

“…As our results indicate, at least part of NEO212’s cytotoxic impact is based on DNA alkylation by its TMZ subunit. This raises the issue of the risk of treatment-related AML (t-AML), a rare condition where AML arises secondary to treatment of other tumors with alkylating agents [ 25 ]. In the context of relapsed and refractory leukemia, it appears that this risk is acceptable in view of the potential benefits that may be derived from certain alkylating agents.…”

Incidental identification of inv(16)(p13.1q22)/CBFB–MYH11 variant transcript in a patient with therapy-related acute myeloid leukemia by routine leukemia translocation panel screen: implications for diagnosis and therapy

“…Therapy for a patient with t-AML is typically tailored to each individual based on cytogenetic risk and performance status ( Dhakal et al 2020 ). Intensive chemotherapy, including CPX-351 or 7 + 3, is typically used in patients with good performance status, whereas older adults or patients with poor performance status may benefit more from low-intensity regimens (hypomethylating agent or low-dose cytarabine with or without venetoclax) ( Boddu et al 2017 ; Lancet et al 2018 ; DiNardo et al 2019 ; Dhakal et al 2020 ). Importantly, in our patient, the detection of inv(16) resulted in induction therapy with cladribine, idarubicin, and cytarabine and consolidation with a high-dose cytarabine based regimen, essentially FLAG (fludarabine, high-dose cytarabine, and granulocyte colony-stimulating factor).…”

Therapy-Related Acute Myeloid Leukemia Following TCHP Chemotherapy in Two HER2+ Breast Cancer Patients

“…Harboring this mutation is linked to intrinsic therapy resistance and worse overall prognosis. Differences in cytogenetics between t-AML in comparison with de novo AML also included a higher incidence of mutations in PTPN11 and a lower incidence of FLT3 and NPM1 [13].…”

“…The treatment for t-AML is tailored to the patient based upon age, comorbidities, performance status, and cytogenetic features. Patients with t-AML have an unfavorable prognosis with a median survival of eight to 10 months after diagnosis [10][11]13]. The only curative therapy is allogeneic bone marrow transplantation following induction chemotherapy with daunorubicin-cytarabine (CPX-351) [13].…”